Carfilzomib-lenalidomide-dexamethasone Vs. lenalidomide-dexamethasone in non-frail transplant-ineligible patients with newly diagnosed multiple myeloma: the EMN20 trial

被引：0

作者：

D'Agostino, Mattia ^{[1
,2
]}

Antonioli, Elisabetta ^{[3
]}

Gamberi, Barbara ^{[4
]}

Bruno, Benedetto ^{[1
,2
]}

Derudas, Daniele ^{[5
]}

Tosi, Patrizia ^{[6
]}

Fazio, Francesca ^{[7
]}

Carlo-Stella, Carmelo ^{[8
,9
]}

Ronconi, Sonia ^{[10
]}

Corradini, Paolo ^{[11
]}

Ballanti, Stelvio ^{[12
]}

Cellini, Claudia ^{[13
]}

Falcone, Antonietta Pia ^{[14
]}

Bringhen, Sara ^{[15
]}

Offidani, Massimo ^{[16
]}

Rambaldi, Alessandro ^{[17
]}

Rota-Scalabrini, Delia ^{[18
]}

Agazzi, Alberto ^{[19
]}

Casaluci, Gloria Margiotta ^{[20
]}

Pietrantuono, Giuseppe ^{[21
]}

Patriarca, Francesca ^{[22
,23
]}

Larocca, Alessandra ^{[2
,15
]}

Boccadoro, Mario ^{[24
]}

机构：

[1] Azienda Osped Univ Citta Salute & Sci Torino, Div Hematol, Turin, Italy

[2] Univ Torino, Div Hematol, Dept Mol Biotechnol & Hlth Sci, Turin, Italy

[3] AOU Careggi, UO Ematol, Florence, Italy

[4] Azienda USL IRCCS Reggio Emilia, Reggio Emilia, Italy

[5] ARNAS G Brozu, Osped Oncol Riferimento Reg A Businco, SC Ematol & CTMO, Cagliari, Italy

[6] Osped Rimini, UO Ematol, Rimini, Italy

[7] Sapienza Univ Rome, Dept Translat & Precis Med, Hematol, Rome, Italy

[8] Humanitas Clin & Res Ctr, Dept Oncol & Hematol, Humanitas Canc Ctr, Rozzano, Italy

[9] Humanitas Univ, Dept Biomed Sci, Rozzano, Italy

[10] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amado, Meldola, Italy

[11] Fdn IRCCS Ist Nazl Tumori, Milan, MI, Italy

[12] Osped Santa Maria Misericordia, Sez Ematol & Immunol Clin, Localita St Andrea Fratte, Perugia, Italy

[13] Osped Santa Maria Croci, UOC Ematol, AUSL Romagna, Ravenna, Italy

[14] IRCCS Casa Sollievo della Sofferenza Hosp, Hematol, San Giovanni Rotondo, Italy

[15] Azienda Osped Univ Citta Salute & Sci Torino, Dept Oncol, SSD Clin Trial Oncoematol & Mieloma Multiplo, Turin, Italy

[16] Azienda Osped Univ Marche, Clin Ematol, Ancona, Italy

[17] ASST Papa Giovanni XXIII, UO Ematol, Bergamo, Italy

[18] FPO IRCCS, Candiolo Canc Inst, Dept Med Oncol, Turin, Italy

[19] European Inst Oncol, Hematoncol Div, Milan, Italy

[20] AOU Maggiore Carita, Novara, Italy

[21] IRCCS Ctr Riferimento Oncol Basilicata, Hematol & Stem Cell Transplantat Unit, Rionero In Vulture, Italy

[22] Univ Udine, Dipartimento Area Med DAME, ASUFC, Clin Ematol, Udine, Italy

[23] Univ Udine, Unita Terapie Cellulari, ASUFC, Clin Ematol, Udine, Italy

[24] European Myeloma Network, Milan, Italy

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-109

引用

页码：S94 / S95

页数：2

共 50 条

[21] Daratumumab, lenalidomide, and dexamethasone in Japanese patients with transplant-ineligible newly diagnosed multiple myeloma: a phase 1b study
Takamatsu, Hiroyuki
Iida, Shinsuke
Shibayama, Hirohiko
Shibayama, Kazuhiro
Yamazaki, Hiroshi
Suzuki, Kenshi
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 111 (05) : 692 - 701
[22] A Phase II Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD lite) for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
O'Donnell, Elizabeth
Laubach, Jacob P.
Yee, Andrew J.
Huff, Carol Ann
Basile, Frank
Wade, Philip M.
Paba-Prada, Claudia E.
Ghobrial, Irene M.
Schlossman, Robert L.
Couture, Nicole
Doherty, Lauren
Lyons, Hannah
English, Caroline
Munshi, Nikhil
Anderson, Kenneth C.
Richardson, Paul G.
Raje, Noopur
BLOOD, 2014, 124 (21)
[23] Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes
Facon, Thierry
Moreau, Philippe
Weisel, Katja
Goldschmidt, Hartmut
Usmani, Saad Z.
Chari, Ajai
Plesner, Torben
Orlowski, Robert Z.
Bahlis, Nizar
Basu, Supratik
Hulin, Cyrille
Quach, Hang
O'Dwyer, Michael
Perrot, Aurore
Jacquet, Caroline
Venner, Christopher P.
Raje, Noopur
Tiab, Mourad
Macro, Margaret
Frenzel, Laurent
Leleu, Xavier
Cook, Gordon
Wang, George
Pei, Huiling
Krevvata, Maria
Carson, Robin
Borgsten, Fredrik
Kumar, Shaji K.
LEUKEMIA, 2025, : 942 - 950
[24] Carfilzomib-lenalidomide-dexamethasone (KRd) vs carfilzomib-cyclophosphamide-dexamethasone (KCd) induction: Planned interim analysis of the randomized FORTE trial in newly diagnosed multiple myeloma (NDMM).
Gay, Francesca Maria
Scalabrini, Delia Rota
Belotti, Angelo
Offidani, Massimo
Petrucci, Maria Teresa
Esma, Fabrizio
Palmas, Angelo D.
Caravita, Tommaso
Grasso, Mariella
Aquino, Sara
Gamberi, Barbara
Zambello, Renato
Ledda, Antonio
Montefusco, Vittorio
Omede, Paola
Galli, Monica
Cavo, Michele
Palumbo, Antonio
Musto, Pellegrino
Boccadoro, Mario
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[25] Daratumumab, lenalidomide, and dexamethasone in Japanese patients with transplant-ineligible newly diagnosed multiple myeloma: a phase 1b study
Hiroyuki Takamatsu
Shinsuke Iida
Hirohiko Shibayama
Kazuhiro Shibayama
Hiroshi Yamazaki
Kenshi Suzuki
International Journal of Hematology, 2020, 111 : 692 - 701
[26] Continuous Treatment with Lenalidomide and Low-Dose Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma in Asia: Subanalysis of the First Trial
Lu, Jin
Lee, Jae Hoon
Huang, Shang-Yi
Qiu, Lugui
Lee, Je-Jung
Liu, Ting
Yoon, Sung-Soo
Kim, Kihyun
Shen, Zhi Xiang
Eom, HyeonSeok
Chen, Wenming
Min, Chang-Ki
Kim, Hyo Jung
Lee, Jeong Ok
Kwak, Jae Yong
Yiu, Wai
Chen, Guang
Haynes, Annette Ervin
Hulin, Cyrille
Facon, Thierry
BLOOD, 2015, 126 (23)
[27] Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) vs daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd) as induction therapy in newly diagnosed multiple myeloma
Tan, Carlyn Rose
Maclachlan, Kylee
Nemirovsky, David
Derkach, Andriy
Hultcrantz, Malin
Hassoun, Hani
Mailankody, Sham
Shah, Urvi
Patel, Dhwani
Shekarkhand, Tala
Rueda, Colin
Lahoud, Oscar
Shah, Gunjan
Scordo, Michael
Chung, David
Landau, Heather
Giralt, Sergio
Usmani, Saad
Lesokhin, Alexander
Korde, Neha
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S127 - S127
[28] Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial
Lu, Jin
Lee, Jae H.
Huang, Shang-Yi
Qiu, Lugui
Lee, Je-Jung
Liu, Ting
Yoon, Sung-Soo
Kim, Kihyun
Shen, Zhi X.
Eom, Hyeon S.
Chen, Wen M.
Min, Chang K.
Kim, Hyo J.
Lee, Jeong O.
Kwak, Jae Y.
Yiu, Wai
Chen, Guang
Ervin-Haynes, Annette
Hulin, Cyrille
Facon, Thierry
BRITISH JOURNAL OF HAEMATOLOGY, 2017, 176 (05) : 743 - 749
[29] Phase 3 MAIA Study: Overall Survival (OS) Results with Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TIE-NDMM)
Orlowski, Robert
Facon, Thierry
Kumar, Shaji
Plesner, Torben
Moreau, Philippe
Bahlis, Nizar
Basu, Supratik
Nahi, Hareth
Hulin, Cyrille
Quach, Hang
Goldschmidt, Hartmut
O'Dwyer, Michael
Perrot, Aurore
Venner, Christopher
Weisel, Katja
Mace, Joseph
Raje, Noopur
Tiab, Mourad
Macro, Margaret
Frenzel, Laurent
Leleu, Xavier
Ahmadi, Tahamtan
Wang, Jianping
Van Rampelbergh, Rian
Uhlar, Clarissa
Tromp, Brenda
Delioukina, Maria
Vermeulen, Jessica
Usmani, Saad
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S424 - S425
[30] THE FIRST TRIAL: ANALYSIS OF THE ASIAN SUBGROUP OF TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH CONTINUOUS LENALIDOMIDE AND LOW-DOSE DEXAMETHASONE
Lu, J.
Lee, J. H.
Huang, S. Y.
Qiu, L.
Lee, J. J.
Liu, T.
Yoon, S. S.
Kim, K.
Shen, Z. X.
Eom, H. S.
Chen, W. M.
Min, C. K.
Kim, H. J.
Lee, J. O.
Kwak, J. Y.
Yiu, W.
Chen, G.
Ervin-Haynes, A.
Hulin, C.
Facon, T.
HAEMATOLOGICA, 2016, 101 : 548 - 549

← 1 2 3 4 5 →